

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 December 2022 (01.12.2022)



(10) International Publication Number
WO 2022/248573 A3

(51) International Patent Classification:
C12Q 1/6883 (2018.01)

(21) International Application Number:
PCT/EP2022/064247

(22) International Filing Date:
25 May 2022 (25.05.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
21305713.6 28 May 2021 (28.05.2021) EP

(71) Applicants: **CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES** [FR/FR]; 5 allée de l'Île Gloriette, 44093 Nantes CEDEX 1 (FR). **UNIVERSITÉ DE NANTES** [FR/FR]; 1 quai de Tourville, 44000 Nantes (FR). **INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)** [FR/FR]; 101 rue de Tolbiac, 75654 Paris CEDEX 13 (FR).

(72) Inventors: **BROUARD, Sophie**; c/o NANTES UNIVERSITÉ, 1 quai de Tourville, 44000 Nantes (FR). **DANGER, Richard**; c/o NANTES UNIVERSITÉ, 1 quai de Tourville, 44000 Nantes (FR). **GIRAL, Magali**; c/o NANTES UNIVERSITÉ, 1 quai de Tourville, 44000 Nantes (FR).

(74) Agent: **ICOSA**; 83 avenue Denfert-Rochereau, 75014 Paris (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
— with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:
23 February 2023 (23.02.2023)

(54) Title: NON-INVASIVE DIAGNOSIS OF SUBCLINICAL REJECTION

(57) Abstract: The invention described herein relates to methods of diagnosing subclinical rejection, based on the level, amount or concentration of two genes, *AKRIC3* and *TCL1A*, whether independently from each other or in combination. When in combination, the level, amount or concentration of the two genes can further be combined with clinical parameters in the form of a composite score. The invention further provides methods for treating subclinical rejection in a subject if/when the subject was diagnosed with subclinical rejection using the method of the invention; as well as a computer system and a kit-of-parts for implementing the method of diagnosing subclinical rejection.

WO 2022/248573 A3